AvePoint Completes Redemption of Public Warrants, Generates $12.1 Million in Proceeds

AvePoint has completed the redemption of its publicly traded warrants, which were issued in 2019 as part of its initial public offering. The redemption price was $0.01 per warrant, and a total of 189,496 warrants remained unexercised. AvePoint received approximately $12.1 million from the warrant exercises and had 211,879,134 shares of common stock outstanding after the redemption. The warrants ceased trading on the Nasdaq Global Select Market and will be delisted.

The Nasdaq Stock Market has announced the delisting of several companies' securities due to prolonged trading suspensions. This move comes after the exchange provided transparency about the status of multiple companies' stocks, signaling oversight in maintaining market standards. The delisted companies include NKGen Biotech, Inc., Aquaron Acquisition Corp., Bannix Acquisition Corp., Avenue Therapeutics, Inc., WinVest Acquisition Corp., IMAC Holdings, Inc., Lytus Technologies Holdings PTV Ltd., Luokung Technology Corp., Aptose Biosciences, Inc., Virpax Pharmaceuticals, Inc., ClimateRock, Phoenix Motor Inc., AI TRANSPORTATION ACQUISITION CORP, Denali Capital Acquisition Corp., Thunder Power Holdings, Inc., Charles & Colvard Ltd., Yotta Acquisition Corporation, Heramba Electric plc, Cumulus Media Inc., Aimfinity Investment Corp I, Starbox Group Holdings Ltd., Zoomcar Holdings, Inc., ConnectM Technology Solutions, Inc., Investcorp AI Acquisition Corp, Cartesian Growth Corporation II, Hepion Pharmaceuticals, Inc., Accelerate Diagnostics, Inc., Affimed N.V., AppTech Payments Corp., Damon Inc., Zapp Electric Vehicles Group Limited, LeddarTech Holdings Inc., and Marin Software Incorporated [1].

Meanwhile, AvePoint has completed the redemption of its publicly traded warrants, which were issued in 2019 as part of its initial public offering. The redemption price was $0.01 per warrant, and a total of 189,496 warrants remained unexercised. AvePoint received approximately $12.1 million from the warrant exercises and had 211,879,134 shares of common stock outstanding after the redemption. The warrants ceased trading on the Nasdaq Global Select Market and will be delisted [2].

The delisting of these companies' securities may lead to a loss of investor confidence and damage the companies' reputations. The mass delisting could suggest broader market issues or concerns regarding the performance and compliance of these companies within the Nasdaq framework. Nasdaq's transparency about the status of these stocks indicates a commitment to maintaining high standards and regulatory compliance [1].

References:
[1] https://www.quiverquant.com/news/Nasdaq+Announces+Delisting+of+Multiple+Companies+Including+NKGen+Biotech%2C+Aquaron+Acquisition+Corp%2C+and+Others
[2] https://www.avepoint.com/news/avepoint-completes-redemption-of-its-publicly-traded-warrants